Dr. Sudhir Chandra Sarangi is a clinical pharmacologist with expertise spanning Clinical Pharmacology, Neuropsychopharmacology, Pharmacovigilance, Drug Safety, Pharmacogenetics, Pharmacoeconomics, and Computational Pharmacology. He has contributed to over 50 research papers in indexed journals, 10 book chapters, and holds six patents, with an H-index of 16, i10-index of 21, and 606 citations. Dr. Sarangi has received multiple awards, including the Best Poster Award at ISCOMS 2024 (Groningen, The Netherlands) and Best Paper Awards at the Joint Annual Conference of the Indian Epilepsy Society and Indian Epilepsy Association (ECON 2021, 2023). He has been awarded bursaries from the 34th and 35th International Epilepsy Congresses and received ICMR International Travel support to attend the 33rd International Epilepsy Congress in Bangkok, Thailand. He serves as Deputy Coordinator of the Pharmacovigilance and Materiovigilance program at AIIMS, New Delhi, and is an executive committee member of the Indian Epilepsy Society. He is also a member of the SAE subcommittee of the Institute Ethics Committee and an inspector in the GLP program under NGCMA, DST, Government of India. Dr. Sarangi is an active member of the National Academy of Medical Sciences (India), Indian Epilepsy Society, Indian Pharmacology Society, Indian Society of Rational Pharmacotherapeutics, The Association of Physiologists & Pharmacologists of India, Society of Toxicology (India), Indian Society of Nanomedicine, and the Delhi Pharmacological Society.

Dr. Peng-fei Wu is a Professor in the Department of Pharmacology, School of Basic Medicine, Tongji Medical College at Huazhong University of Science and Technology. His research focuses on: 1) Metabolic Neuropharmacology, 2) Mechanisms and Novel Therapeutic Strategies for Stress-Related Psychiatric Disorders, and 3) Chemical-Biological Psychiatry.

Dr. Rashmi Patil holds a PhD in Pharmacology from Poona College of Pharmacy, BVDU, India. Her research work has mainly focused on neuroscience, with special emphasis on metabolic diseases-induced depression. She has published research papers and presented her work at international conferences. Alongside her interest in pharmacology, she is skilled in illustration, thereby bridging the gap between science and the general public and making science more accessible and understandable. She is presently a Global Art in Medicine Coordinator and a member of the World Women in Neuroscience Committee.

Dr. Christine Hsieh is a Postdoctoral Research Fellow at the Taipei Neuroscience Institute, Taipei Medical University, Taiwan. Her research focuses on molecular neuroscience and the pathological mechanisms underlying epilepsy, neurodevelopmental, and neuropsychiatric disorders. She received her PhD from the National Yang Ming Chiao Tung University in collaboration with Academia Sinica, where her doctoral work investigated the molecular and neurobiological basis of the genetic disease tuberous sclerosis complex (TSC) using advanced neuroimaging approaches, complemented by histological and molecular validations. Following her PhD, she continued to study TSC and expanded her research to evaluate the therapeutic potential of a novel small-molecule compound, J4, for TSC-related neurological manifestations. Dr. Hsieh has published three peer-reviewed research articles on TSC and related brain pathologies. Her current research interests center on translational neuroscience, with a particular emphasis on mechanism-based drug discovery for developmental and cognitive brain disorders.

Dr. Hemanth Kumar Boyina is a Professor of Pharmacology at Chandigarh University, Punjab, India, with over 15 +years of experience in teaching and research. His expertise lies in neuropharmacology and translational neuroscience, focusing on neurodegenerative and neurological disorders such as Alzheimer’s disease, Parkinson’s disease, vascular dementia, and depression models. He has international research experience as a SERB-SIRE Visiting Fellow at the University of California, San Diego, USA, where he investigated molecular mechanisms of neuroprotection in Alzheimer’s disease. His research integrates behavioral neuroscience, molecular biology, and nanomedicine-based drug delivery. Dr. Boyina has published over 20 + research and review articles and actively mentors undergraduate, postgraduate, and doctoral students. His current interests include natural product-based therapeutics and computational pharmacology for CNS and metabolic disorders.

Dr. Li-Hong Long is the Professor of Department of Pharmacology, School of Basic Medicine, Huazhong University of Science and Technology.. She became faculty at Huazhong University in 2002, where she earned PhD degree in 2007 and moved up the ranks. From March 2012 to April 2014, she worked as a visiting associate professor at Yale Medical School. Her work focuses on the mechanism neuropsychological disease to find potential therapeutic targets, with special interest in metabolic underpinnings to protect against anxiety and depression. Her recent publication could be found in Nature metabolism, Journal of Clinical Investigation, Advanced Science and Signal Transduction and Targeted Therapy.